What are we trying to treat?
That's a useful place to begin. Ozempic contains semaglutide; this injectable medicine has approved uses for adults living with type 2 diabetes. Wegovy (semaglutide) has weight-management uses in adults with obesity, or overweight plus a weight-related condition. The Ozempic label and Wegovy label set out the full uses and conditions.
“Which benefit are we aiming for?” gives the appointment a clearer purpose. A familiar medicine name isn't the whole answer.
What health history matters?
The Wegovy label rules out use with a personal or family history of medullary thyroid carcinoma, a particular thyroid cancer, or MEN 2, an inherited condition affecting hormone-producing glands. It also rules out a previous serious allergy to semaglutide or another ingredient. These are label restrictions, rather than a checklist that can approve treatment here.
Other questions involve pancreas or gallbladder trouble, severe slow stomach emptying, diabetic eye disease, pregnancy plans and upcoming surgery. The provider needs the details, including other medicines you're taking.
What does a prescription change about a compounded medicine?
Compounded medicines are not FDA-approved, even with a prescription. The FDA doesn't check their safety, effectiveness or quality before marketing. Compounding can meet a medical need an approved product can't meet, but a prescription doesn't turn it into an approved generic. The FDA's compounding explanation spells out the difference.
A useful question is: Why is this preparation being considered for me? A familiar ingredient name doesn't show that a compounded product will give the same results as the manufactured medicine used in a trial.
What about copies of approved medicines?
The FDA's April 2026 update describes limits on compounding medicines that are essentially copies.
Under 503A, the patient-specific compounding route, it describes a preparation that falls outside the copy definition: the prescriber determines and documents that a change produces a significant difference for an identified patient compared with the commercially available product.
A prescription alone doesn't establish that difference, and adding a vitamin doesn't automatically establish it either. The FDA's policy explanation gives the detail; this guide can't judge an individual prescription's legal position.
What would happen after the first appointment?
This part of the conversation deserves time too. How would side effects be reviewed? Who could answer questions between visits? What would happen if treatment needed to change?
The effects page explains why the longer view matters, including weight regain after treatment stopped in a study. The doses page explains why a study number can't supply a personal plan. It's fine to arrive with questions still open.